1. Home
  2. UEIC vs EDSA Comparison

UEIC vs EDSA Comparison

Compare UEIC & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

UEIC

Universal Electronics Inc.

HOLD

Current Price

$4.31

Market Cap

60.6M

ML Signal

HOLD

Logo Edesa Biotech Inc.

EDSA

Edesa Biotech Inc.

HOLD

Current Price

$4.80

Market Cap

51.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UEIC
EDSA
Founded
1986
2015
Country
United States
Canada
Employees
N/A
N/A
Industry
Consumer Electronics/Appliances
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
60.6M
51.5M
IPO Year
1995
2018

Fundamental Metrics

Financial Performance
Metric
UEIC
EDSA
Price
$4.31
$4.80
Analyst Decision
Hold
Strong Buy
Analyst Count
1
1
Target Price
$3.50
$5.00
AVG Volume (30 Days)
97.9K
75.8K
Earning Date
05-07-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
23.78
N/A
EPS
N/A
N/A
Revenue
$368,288,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.69
$0.72
52 Week High
$5.99
$20.32

Technical Indicators

Market Signals
Indicator
UEIC
EDSA
Relative Strength Index (RSI) 38.77 41.16
Support Level $3.87 $4.80
Resistance Level $4.43 $6.62
Average True Range (ATR) 0.33 0.63
MACD -0.11 0.00
Stochastic Oscillator 4.35 26.67

Price Performance

Historical Comparison
UEIC
EDSA

About UEIC Universal Electronics Inc.

Universal Electronics Inc is engaged in universal wireless control solutions for the home. The company design, develop, manufacture, ship and support climate control solutions, wireless sensor and smart home control products, home entertainment control products, technology and software solutions and audio-video (AV) accessories that are used by the world's brands in the climate control, security, home automation, home appliance, home entertainment and consumer electronics markets.

About EDSA Edesa Biotech Inc.

Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.

Share on Social Networks: